Netrina-1: Su posible uso terapéutico sobre el desarrollo de la aterosclerosis / Netrina-1: Its posible therapeutic use on the development of atherosclerosis
Texto completo:
PDF
Resumen
Palabras clave: Aterosclerosis; monocito; macrófagos; Netrina-1.
Abstract
A bibliography revision was carry out in 14 articles and two books about the pathological processes that contributes in the formation of the atherosclerosis and they valorized the effects of the netrina-1 about the pathogen and its possible therapeutic use. The atherosclerosis is clinically important because it constitutes in the base of the pathogen of the chronic diseases that presents a high rate of morbidity and mortality in relation with whichever other disease in the occidental world. The cause of the development of the atherosclerosis is multifactorial that includes different factors like: individual lifestyle, biological factors and genetics. The past years they demonstrated that the netrina-1 protein is a key modulator for the pathological process of atherosclerosis since it inhibits the formation of the atheroma plate. An atheroma plate is mainly a deposition of elevated cholesterol in the intimate tunic. Therefore, it has been shown that the role of monocytes in the development of atherosclerosis as well as the high-density lipoprotein administration is potential factors for therapeutic intervention. Therefore, many of the medical advances are aimed at the cure of various pathogens conducted by these cardiovascular disorders.
Key words: atherosclerosis; monocytes; macrophages; netrina-1.
Palabras clave
Referencias
World Health Organizations (WHO). Cardiovascular diseases [Internet]. 2016 [citado marzo 4 2017].Disponible en: http://www.who.int/mediacentre/factsheets/fs317/es/
Kumar V, Abbas AK, Fausto N, Aster J: Robbins. Basic Pathology. 10th. Ed. Philadelphia: Elseviers Saunders; 2017. Cap 10, p 369-378
Hidalgo R. Nancy, et al. PatologÃa general: Editorial Ciencias Médicas, La Habana, Cuba. 2014.Cap 8, p. 149-154
Gerszten R. E, A. M. Tager. The monocyte in Atherosclerosis-Should I stay or should I go now? N Engl J Med 2012;366:1734-36
K. Layne et al. Netrin-1 as a novel therapeutic target in cardiovascular disease: to actÃvate or inhibit?. Cardiovascular Research 2018; 107:410-419.
Moore J. Kathryn. Fisher A. Edward. Macrophages, aterosclerosis and the potential of netrin as a novel target for future therapeutic intervention. National institute of health. New York, NY.2016
Khan JA, Cao M. Kang BY, Liu Y, Mehta JL, Hermonat PL. Systemic human Netrin-1 gene delivery by adeno-associated virus type 8 alters leukocyte accumulation and atherogenesis in vivo. Gene Ther 2011; 18:437-444.
Randolph GJ. The fate of monocyte in atherosclerosis J Thromb Haemost. 2009; 7(Suppl 1): 28-30
Jaipersad AS, Lip GY, Silverman S. The role of Monocytes in Angiogenesis and Atherosclerosis. J Am Coll Cardiol. 2014; 63(1):1-11.
Feig JE. Regression of Atherosclerosis: Insights from Animal and Clinical Studies. Ann Glob Health. 2014; 80(1): 13-23.
Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiciology: opening the X-files. Science. 2001; 294: 1866-70.
Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med. 2006; 57: 313-29.
Hilgendorf I, Swirski F, Robbins C. Monocyte Fate in Atherosclerosis. Aterioscler Thromb Vasc Biol. 2015; 35: 272-279.
Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes in Coronary Artery Disease and Atherosclerosis. J Am Coll Cardiol. 2013; 62(17):1541-51.
Tardif JC, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. Jama. 2007; 297(15):1675–82
Camaré C, Pucelle M, Nègre-Salvayre A, Salvayre R. Angiogenesis in the atherosclerotic plaque. Redox Biology. 2017; 12: 18-34.